Skip to content

Travere Therapeutics Inc

TVTX

Latest QuantConomy context for TVTX: asset profile, market coverage, scored signals, and source-linked SEC insider filings when available.

Asset class
stock
Primary venue
NASDAQ
Recent signals
3
SEC filings
20
Asset profile

Travere Therapeutics Inc

QuantConomy has a structured record for TVTX. More descriptive asset metadata will appear here when the platform record includes it.

Symbol
TVTX
Name
Travere Therapeutics Inc
Coverage
3 market/data records
Sources
alpaca alphavantage fmp sec nasdaq openfigi
Latest signal rows

Recent signals for TVTX

Scored rows are pulled from the same signal API used by the digests.

Signal Direction Score Observed Reason
earnings release
neutral
40
Jan 12, 12:00 AM TVTX filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-01-12. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).
earnings release
neutral
40
Feb 19, 12:00 AM TVTX filed an earnings release (8-K Item 2.02 - Results of Operations and Financial Condition) on 2026-02-19. Release-event signal only: confirms results were published, not the figures vs. estimates (no surprise/guidance read).
executive change
neutral
75
Jun 16, 08:40 PM TVTX filed 8-K: Director or Officer Changes - 1 material event - [strong neutral signal]

EARNINGS signals are experimental: currently limited to neutral pre-earnings calendar awareness (no transcript analysis).

PRICE signals are experimental: realized 30-day directional accuracy is ~18% (short-horizon price moves tend to mean-revert). They are automatically down-weighted in composite scores but served raw here. Do not use them as standalone trade advice.

Market coverage

Market Exchange Source Asset record
TVTX NASDAQ alpaca Travere Therapeutics, Inc. Common Stock
TVTX NASDAQ alphavantage Travere Therapeutics Inc
TVTX NASDAQ fmp Travere Therapeutics, Inc.

Recent insider transactions

Buys, last 90d
0
Sells, last 90d
1
Rows
20
Date Insider Role Type Shares Price Value Filing
Jun 22, 2026 Inrig Jula CHIEF MEDICAL OFFICER gift 468 $0.00 $0 4 on EDGAR
Jun 12, 2026 Coughlin Timothy Director exercise 10,000 $26.52 $265,200 4 on EDGAR
May 19, 2026 LYONS GARY A Director grant 4,000 $0.00 $0 4 on EDGAR
May 19, 2026 Poole Sandra Director grant 4,000 $0.00 $0 4 on EDGAR
May 19, 2026 Williams Brinkley Ruth Director grant 4,000 $0.00 $0 4 on EDGAR
May 19, 2026 Squarer Ron Director grant 4,000 $0.00 $0 4 on EDGAR
May 19, 2026 Bruhn Suzanne Louise Director grant 4,000 $0.00 $0 4 on EDGAR
May 19, 2026 Baynes Roy D. Director grant 4,000 $0.00 $0 4 on EDGAR
May 19, 2026 Coughlin Timothy Director grant 4,000 $0.00 $0 4 on EDGAR
May 19, 2026 Meckler Jeffrey A Director grant 4,000 $0.00 $0 4 on EDGAR
May 19, 2026 Orwin John A Director grant 4,000 $0.00 $0 4 on EDGAR
May 15, 2026 Coughlin Timothy Director sale 3,250 $43.49 $141,343 4 on EDGAR
May 5, 2026 Baynes Roy D. Director exercise 4,500 $18.27 $82,215 4 on EDGAR
May 4, 2026 Heerma Peter CHIEF COMMERCIAL OFFICER exercise 4,250 $0.00 $0 4 on EDGAR
May 4, 2026 Dube Eric M CHIEF EXECUTIVE OFFICER exercise 22,500 $0.00 $0 4 on EDGAR
May 4, 2026 Inrig Jula CHIEF MEDICAL OFFICER exercise 20,000 $22.40 $448,000 4 on EDGAR
May 4, 2026 Meckler Jeffrey A Director exercise 8,000 $16.33 $130,640 4 on EDGAR
May 4, 2026 Cline Christopher R. CHIEF FINANCIAL OFFICER exercise 4,250 $0.00 $0 4 on EDGAR
May 4, 2026 ROTE WILLIAM E. Chief Research Officer exercise 4,250 $0.00 $0 4 on EDGAR
May 4, 2026 REED ELIZABETH E Chief Legal Officer and GC exercise 20,000 $17.96 $359,200 4 on EDGAR

Source: SEC filings via QuantConomy. Not investment advice.

Get the data

Query TVTX context like a database.

These rows come from the QuantConomy signal, asset, market, and SEC filings API surfaces, also available to AI agents over MCP.

No spam, no noise. Just the launch and the occasional preview.

More: All insider trades · How to read a Form 4 · API access